Bioceres Crop Solutions Dirección
Dirección controles de criterios 0/4
El CEO de Bioceres Crop Solutions es Federico Trucco, nombrado en Jun 2011, tiene una permanencia de 14.92 años. posee directamente un 0.59% de las acciones de la empresa, con un valor de $167.95K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 2.2 años, respectivamente.
Información clave
Federico Trucco
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 14.9yrs |
| Participación del CEO | 0.6% |
| Permanencia media de la dirección | 1.3yrs |
| Promedio de permanencia en la Junta Directiva | 2.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Investors Don't See Light At End Of Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Tunnel And Push Stock Down 54%
Feb 10
BIOX: Portfolio Recapitalization Progress Will Eventually Overcome Argentina Liquidity Headwinds
Analysts have trimmed their price target on Bioceres Crop Solutions by roughly $0.10 per share, citing heightened Argentina-related liquidity volatility and increased uncertainty around the company’s portfolio recapitalization efforts. Analyst Commentary Analysts acknowledge that Bioceres retains a differentiated portfolio and strategic exposure to key agricultural markets, but sentiment has turned more cautious as near term risks have become more prominent in their valuation work.BIOX: Next Generation Product Pipeline Will Offset Argentina Liquidity Pressures
Analysts have trimmed their price target on Bioceres Crop Solutions to around $2.25 from approximately $3.63, reflecting concerns over Argentina related liquidity pressures and portfolio recapitalization challenges, even as they continue to see long term value in the company’s next generation product pipeline. Analyst Commentary Street research on Bioceres Crop Solutions reflects a mixed backdrop, with liquidity concerns and execution risks in Argentina offset by continued confidence in the long term earnings power of its next generation product portfolio.BIOX: Portfolio Recapitalization Will Overcome Argentina Liquidity Pressure Ahead
The analyst price target for Bioceres Crop Solutions was revised downward from $3.75 to $3.63. Analysts cited increased pressure from liquidity concerns and recent portfolio challenges as key factors for the adjustment.Is Bioceres Crop Solutions (NASDAQ:BIOX) A Risky Investment?
Nov 17BIOX: Recovery From Argentina Volatility Will Drive Future Upside Potential
Analysts have lowered their fair value price target for Bioceres Crop Solutions from $4.17 to $3.75 per share. They cite concerns about Argentina's economic volatility, recent earnings shortfalls, and increased hurdles to the company's portfolio strategy.Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Oct 30Transition To Capital-Light Model And Global Expansion Will Shape Future Success
Analysts have revised their price target for Bioceres Crop Solutions downward from $8 to $5, citing weaker-than-expected Q4 results and leadership transitions. However, they continue to highlight potential in the company’s pipeline for future value creation.Transition To Capital-Light Model And Global Expansion Will Shape Future Success
Analysts have lowered their price target for Bioceres Crop Solutions from $8 to $5, citing weaker-than-expected Q4 results and concerns over executive turnover. However, they continue to see long-term value in the company's innovation pipeline.The Market Doesn't Like What It Sees From Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Revenues Yet As Shares Tumble 31%
Sep 15Bioceres Crop Solutions: Waiting For Gross Profit To Turn (Downgrade)
Sep 09Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Not Doing Enough For Some Investors As Its Shares Slump 25%
Aug 01Bioceres Crop Solutions (NASDAQ:BIOX) Use Of Debt Could Be Considered Risky
Jul 22Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
Apr 04Bioceres Crop Solutions' (NASDAQ:BIOX) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 07Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Might Not Be As Mispriced As It Looks After Plunging 41%
Mar 05Bioceres Is Approaching Distressed Prices, But I Remain On The Sidelines
Feb 13Bioceres Is Getting Cheaper, Not Yet An Opportunity But More Interesting
Nov 13Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper
Sep 28
HB4 Wheat's US Approval Sparks Global Expansion And Profit Growth Surge
Approval of HB4 Wheat in the US highlights significant expansion and revenue opportunities, enhancing global acceptance and credibility of HB4 technology.Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices
Sep 17These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively
Aug 03Bioceres Needs To Add Clarity Around Borrowings
Mar 23Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt
Feb 03Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
Oct 04Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear
Jun 21Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
May 09Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings
Sep 06Bioceres Crop Solutions jumps 15% after investor pitch
Aug 23We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt
Apr 10Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness
Mar 31Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$59m |
| Sep 30 2025 | n/a | n/a | -US$56m |
| Jun 30 2025 | n/a | n/a | -US$55m |
| Mar 31 2025 | n/a | n/a | -US$9m |
| Dec 31 2024 | n/a | n/a | US$2m |
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | US$4m |
| Mar 31 2024 | n/a | n/a | US$3m |
| Dec 31 2023 | n/a | n/a | US$22m |
| Sep 30 2023 | n/a | n/a | US$14m |
| Jun 30 2023 | n/a | n/a | US$19m |
| Mar 31 2023 | n/a | n/a | US$15m |
| Dec 31 2022 | n/a | n/a | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | -US$7m |
| Mar 31 2022 | n/a | n/a | -US$2m |
| Dec 31 2021 | n/a | n/a | US$4m |
| Sep 30 2021 | n/a | n/a | US$976k |
| Jun 30 2021 | US$659k | US$131k | -US$7m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | n/a | n/a | -US$7m |
| Sep 30 2020 | n/a | n/a | US$3m |
| Jun 30 2020 | US$145k | US$145k | US$3m |
| Mar 31 2020 | n/a | n/a | US$20k |
| Dec 31 2019 | n/a | n/a | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$23m |
| Jun 30 2019 | US$155k | US$155k | -US$18m |
Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Federico es razonable en comparación con empresas de tamaño similar en el mercado US.
Compensación vs. Ingresos: La compensación de Federico ha aumentado mientras la empresa no es rentable.
CEO
Federico Trucco (48 yo)
Dr. Federico Trucco, Ph D., has been Chief Executive Officer of Bioceres Crop Solutions Corp. since June 2011 and served as its Chairman and serves as its Executive Director. He was Head Director of Rizoba...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| General Counsel & Chief Compliance Officer | no data | US$156.00k | sin datos | |
| CEO & Executive Director | 14.9yrs | US$659.42k | 0.59% $ 167.9k | |
| Chief Financial Officer | 1.3yrs | sin datos | sin datos | |
| Principal Accounting Officer | less than a year | sin datos | sin datos | |
| Head of Investor Relations | no data | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de BIOX no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Executive Director | 7.3yrs | US$659.42k | 0.59% $ 167.9k | |
| Non-Executive Director | less than a year | sin datos | sin datos | |
| Non-Executive Director | 3.8yrs | sin datos | 0.087% $ 24.7k | |
| Non-Executive Director | less than a year | sin datos | sin datos |
Junta con experiencia: La junta directiva de BIOX no se considera experimentada (2.2 años de permanencia promedio), lo que sugiere una nueva junta directiva.
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/05 19:34 |
| Precio de las acciones al final del día | 2026/05/05 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bioceres Crop Solutions Corp. está cubierta por 2 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Austin Moeller | Canaccord Genuity |